Pharmaceutical giants have doubled their investments in drug development
in the past decade only to see new drug approvals remain constant. This
book investigates and highlights a set of proactive strategies aimed at
generating sustainable competitive advantage based on value-generating
business practices. We focus on three sources of pharmaceutical
innovation: new management methods in the drug development pipeline, new
technologies as enablers for cutting-edge R&D, and new forms of
cooperation and internationalization, such as open innovation in the
early phases of R&D. Our findings are illustrated by cases from Europe,
the US, and Asia.